Matching articles for "mNEXSPIKE"
COVID-19 Update: mNEXSPIKE — A New Moderna mRNA Vaccine for COVID-19
The Medical Letter on Drugs and Therapeutics • July 21, 2025; (Issue 1733)
The FDA has licensed mNEXSPIKE (Moderna), an
mRNA vaccine, for prevention of COVID-19 in adults
≥65 years old and in persons 12-64 years old who
have a condition that puts them at high risk for
severe...
The FDA has licensed mNEXSPIKE (Moderna), an
mRNA vaccine, for prevention of COVID-19 in adults
≥65 years old and in persons 12-64 years old who
have a condition that puts them at high risk for
severe outcomes from COVID-19. Spikevax, the
original Moderna mRNA COVID-19 vaccine, remains
in production2; it is licensed for use in persons
≥12 years old and is available under an Emergency
Use Authorization (EUA) for children 6 months to
11 years old.